Clinicopathological features and prognosis of patients in endometrial cancer with bone metastases
10.3760/cma.j.issn.0529?567x.2019.07.004
- VernacularTitle:子宫内膜癌骨转移的临床病理特点及预后分析
- Author:
Fang JIANG
1
;
Tong REN
;
Ninghai CHENG
;
Dongyan CAO
;
Jiaxin YANG
;
Ming WU
;
Keng SHEN
;
Yang XIANG
Author Information
1. 中国医学科学院北京协和医学院北京协和医院妇产科100730
- Keywords:
Endometrial neoplasms;
Neoplasm metastasis;
Bone neoplasms;
Treatment outcome;
Retrospective studies
- From:
Chinese Journal of Obstetrics and Gynecology
2019;54(7):452-457
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinicopathological features and prognosis of patients in endometrial cancer with bone metastases. Methods A retrospective review of medical records was performed to analyze patients with endometrial cancer who developed bone metastases at Peking Union Medical College Hospital (PUMCH) from January 2004 to December 2017, including patients with bone metastases at the diagnosis of endometrial cancer and at recurrence of endometrial cancer. The patient′s clinicopathological features, bone metastasis characteristics, treatment process and prognoses were also analyzed. Results The incidence of bone metastasis of endometrial cancer in PUMCH from 2004 to 2017 was 0.57% (14/2 458). (1) General clinical pathological features: the median age of the 7 patients with bone metastases diagnosed at the time of initial diagnosis was 50 years old, and the main pathological type was endometrioid carcinoma (n=5). The median age of the other 7 patients was 57 years old, with no significant difference comparing to the former groups (P=0.559). (2) The majority site of bone metastasis in endometrial cancer were discovered in pelvic bones, followed by the tibia. (3) Treatment: according to the staging of endometrial cancer, a comprehensive treatment based on surgery was performed, and one patient with isolated bone metastases underwent resection of bone metastasis. (4) Prognosis: nine out of the 14 patients died during the follow-up period. The median over all survival time was 25.5 months (range: 7.7-258.0 months). The median survival of population after diagnosis of bone metastases was 15.0 months (range: 3.0-51.0 months). The survival rate of endometrial cancer at 1-year after diagnosis of bone metastasis was 71.4%. The 2-year survival rate was 40.8%. (5) No independent prognostic factors affecting survival was found (P>0.05). Conclusions The incidence of bone metastasis in endometrial cancer is less than 1%. Bone metastasis could occur at the diagnosis of endometrial cancer or recurrence of endometrial cancer. Bone metastasis suggests a poor prognosis. There is no standard follow-up and treatment protocols so that individualized treatment is needed.
